COVID-19 has caused significant disruptions to tuberculosis (TB) services in India – which has the highest burden of TB cases globally. Not only may people with TB be uniquely vulnerable to severe complications from COVID-19, if infected – but the pandemic has also disrupted already-stretched systems of delivering TB care, and lockdowns have made much-needed social support increasingly difficult to come by.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
During the phase II of the COVID-19 pandemic, several patients with symptomatic and asymptomatic cases were reaching the health facilities across Pan India locations, for testing. Though the number of tests conducted per day was increasing, there was a wide gap between the growing number of cases and testing swabs available.
On 22 July 2021, torrential rains battered six districts of Maharashtra Raigad, Ratnagiri, Sindhudurg Kolhapur Sangli and Jalgaon. Heavy rainfall triggered landslides in many places and flooded the rivers, resulting in flooding of vast areas affecting lakhs of people. More than 1020 villages were affected in these districts with no access to drinking water and disrupted power supply. Floods adversely impacted several houses and people were evacuated and shifted to safe places. Thousands of trucks were stuck on National Highway linking Mumbai and Bengaluru in Kolhapur district.